Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

ertion potential through either the femoral or jugular route, which may make the product easier for a physician to use, and the use of non-thrombogenic material which reduces the risk of blood clots occurring in the filter. We also believe the unique design of the Option IVC Filter may allow physicians to remove or retrieve the device from patients more easily, or after longer periods of time have passed as compared to existing competitive IVC filters.

The Option IVC Filter was approved based upon the results of a United States multi-center prospective clinical trial. The purpose of the clinical trial was to evaluate the device's safety and efficacy in preventing pulmonary emboli, and to assess the ability to retrieve the device from the body up to 175 days following implantation. The results, representing a total of 100 patients, were presented at the 2009 Society of Interventional Radiology in San Diego, CA on March 9, 2009. Successful filter implantation was achieved in 100% of the subjects and the retrieval rate in the study was 92.3%. Clinical success, which was achieved in 88% of subjects, was defined as placement of the filter without subsequent pulmonary embolism, significant filter migration or embolization, symptomatic caval thrombosis or other complications requiring filter removal or invasive intervention.

The Option IVC Filter was licensed in March 2008 from our partner Rex Medical L.P. ("Rex Medical"). We are obligated to pay royalties and milestone payments to Rex Medical derived from our sales of the Option IVC Filter. We made a milestone payment of $2.5 million to Rex Medical upon 510(k) clearance of the Option IVC Filter during the second quarter of 2009 and recorded the payment as an intangible asset.

License, Distribution, Development and Supply Agreements with Haemacure Corporation. In June 2009, we announced that we had entered into license, distribution, development and supply agreements for fibrin and thrombin
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic ... complete healing of an otherwise non-healing surgical knee wound. , The case involved ...
(Date:8/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... Kingdom -based Lab M Holdings, a developer, manufacturer ... Lab M was founded in 1971, ... testing and diagnostic products for the global food, water, ... into more than 70 countries worldwide, and has several ...
(Date:8/27/2015)... Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... periods ended June 30, 2015. Biorem,s complete second quarter financial statements ... FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , Six ... , 2015 , 2014 Revenue , ... 4,433 Gross profit , 1,656 , 56 ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... customers’ weighing needs and expertly narrows down the product choices to a manageable ... criteria pares down the list to models that fit best with the customer’s ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Neogen acquires U.K.-based Lab M Holdings 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3METTLER TOLEDO Updates Online Scale Selection Tool 2
... Laboratories,( http://www.microtestlabs.com ) has doubled their microbial ... an additional MicroSeq(R),Microbial Identification System., The ... that,enables Microtest technicians to more quickly and ... or easily identified., "With the purchase ...
... 3 Associates of Cape Cod,Inc. (ACC), a ... announced that the Fungitell(R) assay kit, for the,measurement ... CE marked, which enables distribution in the European ... included in both the Infectious,Disease Society of America,s ...
... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of ... Chief Executive Officer, and,Darlene Deptula-Hicks, Executive Vice President ... a corporate update at the Seventh Annual,Needham and ... 11, 2008 at 2:00 p.m., (Eastern Daylight Time) ...
Cached Biology Technology:Microtest Labs Doubles Microbial Identification, Analytical Services 2Fungitell(R) CE Marked, Referenced in IDSA and NCCN Guidelines and Added to EORTC-MSG Revised Definitions of Invasive Fungal Disease 2Fungitell(R) CE Marked, Referenced in IDSA and NCCN Guidelines and Added to EORTC-MSG Revised Definitions of Invasive Fungal Disease 3iCAD to Present at Seventh Annual Needham and Company Biotechnology and Medical Technology Conference 2
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
(Date:8/18/2015)... PRINCETON, N.J. , Aug. 18, 2015 ... be a key contributor to the Submission ... hosted by IRISS, a non-profit forum. Dedicated to ... IRISS provides a neutral platform for industry, ... to share information and work towards a ...
(Date:8/12/2015)... As the digital payment services ... advanced biometrics technology is accelerating beyond expectations.  While the ... using their credit cards, the digital currency, mobile payment ... services led by companies in the space such as ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... have a mixed reputation. Their delicate, colorful flowers and ... gardeners and growers. But the striking plants are often ... warm temperatures, high humidity, and fertilizer is required to ... recently published study by scientists Julia C. Brotton and ...
... tree native to North America, is native from northern ... the United States, where it grows abundantly along the ... and Texas. Popularity and consumer demand for pecans has ... while commercial production has expanded into many regions of ...
... (Mon., Nov. 2, 2009) -- The introduction of high-throughput ... the genetics of complex diseases. Instead of focusing only ... sample of individuals, the ability to accurately and efficiently genotype ... individual genes has resulted in genetic studies with greater statistical ...
Cached Biology News:For African violets, 'hands off' means healthier 2Sun or shade: Pecan leaves' photosynthetic light response evaluated 2High-throughput genotyping, protein purification featured in Cold Spring Harbor Protocols 2
Request Info...
... Xcell microbial system, 100 to 240 ... electroporation of bacterial and fungal cells. ... PC module for exponential decay delivery, ... (5 each of 0.1 and 0.2 ...
... Species Tissue Array (MSTA) slides were designed to ... tissues from multiple species. Tissue slices from ... slide which can then be treated as a ... in situ hybridization. This format ...
... used to predict the melting ... up to 3,200 bases, which ... primers and GC clamps for ... gel electrophoresis (DGGE), constant denaturing ...
Biology Products: